Physician profile
Michael Manetas
NPI 1275535213
$125,456.72
in general payments reported to CMS, 2019-2025
36 companies · $40K in 2025
The $40K reported for 2025 was more than what 99% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,111 · 2020: $895 · 2021: $10K · 2022: $5,407 · 2023: $24K · 2024: $44K · 2025: $40K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $86K · Food and Beverage: $11K · Travel and Lodging: $10K · Education: $25.20.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $86,172.86 |
| Food and Beverage | $11,211.40 |
| Travel and Lodging | $10,256.58 |
| Education | $25.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $54,997.57 | 2019-2025 | Tremfya, Stelara |
| Abbvie INC. | $29,071.94 | 2019-2025 | |
| Phathom Pharmaceuticals, INC. | $21,085.28 | 2024-2025 | Voquezna |
| Ironwood Pharmaceuticals, INC | $12,839.36 | 2019-2024 | Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,418.70 | 2019-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $1,389.34 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Genzyme Corporation | $1,107.18 | 2022-2025 | |
| Ardelyx, INC. | $573.33 | 2022-2025 | Ibsrela |
| Pfizer INC. | $501.65 | 2019-2025 | |
| Qol Medical, LLC | $373.57 | 2019-2025 | Sucraid, Sucraid |
| Lilly USA, LLC | $241.74 | 2023-2025 | Omvoh |
| E.R. Squibb & Sons, L.L.C. | $237.05 | 2021-2023 | Zeposia |
| Celgene Corporation | $210.44 | 2021-2024 | Zeposia |
| Medtronic, INC. | $147.25 | 2021-2025 | Nexpowder, Interstim, Gi Genius |
| Janssen Scientific Affairs, LLC | $139.98 | 2019-2025 | Tremfya |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $139.14 | 2020-2023 | |
| Novo Nordisk INC | $129.72 | 2023-2025 | Wegovy |
| Intercept Pharmaceuticals, INC. | $97.01 | 2019-2023 | Ocaliva |
| Ferring Pharmaceuticals INC. | $96.86 | 2021-2024 | Rebyota |
| Alnylam Pharmaceuticals INC. | $87.88 | 2019-2023 | Givlaari |
| Merck Sharp & Dohme LLC | $73.29 | 2019-2024 | Dificid |
| Echosens North America, INC. | $62.25 | 2020 | |
| Braintree Laboratories, INC. | $58.45 | 2021-2023 | Sutab, Suflave |
| Ipsen Biopharmaceuticals, INC | $56.07 | 2024-2025 | Iqirvo |
| Blueprint Medicines Corporation | $42.69 | 2024 | Ayvakit |
| Ambu INC. | $37.98 | 2021 | |
| Enterra Medical, INC. | $36.07 | 2025 | |
| Amgen INC. | $33.79 | 2023 | Amjevita |
| Concordia Pharmaceuticals INC. | $30.54 | 2019 | |
| Madrigal Pharmaceuticals | $30.40 | 2024 | Resmetirom |
| Celltrion USA INC. | $29.67 | 2024 | Zymfentra |
| Regeneron Healthcare Solutions, INC. | $25.92 | 2025 | Dupixent |
| Daiichi Sankyo INC. | $19.04 | 2019 | |
| Fujifilm Healthcare Americas Corporation | $14.22 | 2024 | Utaswako Afp-L3 |
| Covidien LP | $11.86 | 2019 | |
| Mauna Kea Technologies, INC. | $9.49 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Manetas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.